Bimekizumab is associated with significant complete clearance rates at 4 years among patients with scalp, nail, or palmoplantar psoriasis.
The ustekinumab biosimilar AVT04 has consistent efficacy through 28 weeks in patients with PsO with and without prior ustekinumab exposure.
Delhi judges face escalating threats with inadequate security, prompting urgent calls for enhanced protection amid growing ...
Over a dozen wind farm projects are now waiting more than a year for a planning decision, while just three have gained ...
Background Patients with psoriasis (PsO) are at increased risk of developing psoriatic arthritis (PsA). Emerging evidence ...
Detailed price information for Evergen Infrastructure Corp (EVGN-X) from The Globe and Mail including charting and trades.
In April, the American Red Cross asks people to keep patients top of mind by making an appointment to give blood or platelets ...
Advanced packaging has created new process bottlenecks related to the internal mechanics of the packaging equipment. As ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results